What is Henoch-Schönlein Purpura (HSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Henoch-Schönlein Purpura (HSP)?

Henoch-Schönlein Purpura (HSP), now termed IgA vasculitis, is an IgA-mediated systemic small-vessel vasculitis characterized by the clinical finding of palpable purpura plus at least one of the following: renal involvement (hematuria and/or proteinuria), arthritis/arthralgia, or abdominal pain. 1, 2

Pathophysiology

  • HSP is caused by deposition of IgA-dominant immune complexes in small blood vessels, leading to leukocytoclastic vasculitis 3, 4
  • The disease involves aberrantly glycosylated IgA1 molecules that form immune complexes, which deposit in the mesangium and subepithelial/subendothelial spaces of glomeruli 5
  • These deposited immune complexes trigger mesangial proliferation and renal damage, likely requiring complement system activation 5

Clinical Presentation

The classic tetrad includes: 4, 6

  • Palpable purpura (non-thrombocytopenic) - typically on lower extremities and buttocks
  • Arthritis or arthralgia - commonly affecting knees and ankles
  • Abdominal pain - may include gastrointestinal bleeding
  • Renal involvement - hematuria and/or proteinuria

Epidemiology

  • HSP is the most common form of systemic vasculitis in children, with an incidence of 10-20 cases per 100,000 children per year 2, 6
  • Approximately 90% of cases occur in children aged 2-10 years, with peak incidence at 4-7 years 2
  • The disease primarily affects children but can occur in adults, though adult-onset is less common and carries worse prognosis 1, 4

Organ System Involvement

Renal manifestations: 5

  • Glomerulonephritis (HSPN) occurs in 30-50% of HSP patients
  • Most cases are mild, but a small percentage present with nephrotic syndrome or renal failure
  • Renal involvement is the most important prognostic factor determining long-term morbidity and mortality 2

Gastrointestinal manifestations: 2

  • Diffuse abdominal pain is common
  • Complications can include gastrointestinal bleeding and intussusception

Musculoskeletal manifestations: 3

  • Arthritis or arthralgia, typically affecting large joints of lower extremities

Other rare manifestations: 7

  • Orchitis, central nervous system involvement, and myocarditis have been reported 6

Diagnostic Approach

Clinical diagnosis is made when palpable purpura is present plus at least one of the following: 1

  • Renal involvement (hematuria and/or proteinuria)
  • Arthralgia or arthritis
  • Abdominal pain
  • Biopsy showing predominant IgA deposition 2

Essential laboratory evaluation includes: 1

  • Urinalysis with microscopy to assess for proteinuria, red blood cell casts, and dysmorphic red blood cells
  • Basic metabolic panel including BUN and serum creatinine to assess renal function
  • Complete blood count with platelets to rule out thrombocytopenia
  • Blood pressure measurement, as hypertension may indicate severe renal involvement

Biopsy findings: 7

  • Immunofluorescence or immunohistochemistry is essential to demonstrate IgA deposition in affected tissues
  • IgA nephropathy/Henoch-Schönlein purpura can be overlooked without proper immunofluorescence studies

Natural History and Prognosis

  • Most cases are self-limited with an average disease duration of 4 weeks 2
  • HSP spontaneously resolves in 94% of children and 89% of adults 6
  • Long-term complications are rare but include persistent hypertension and end-stage kidney disease 2
  • Renal involvement can persist and relapse years after initial presentation, making 6 months of follow-up prudent 6
  • Adults have worse prognosis and higher risk of progression to end-stage renal disease compared to children 1

References

Guideline

Henoch-Schönlein Purpura Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Henoch-Schönlein Purpura in Children: An Updated Review.

Current pediatric reviews, 2020

Research

Presentation of a patient with palpable purpuric rash.

JPMA. The Journal of the Pakistan Medical Association, 2009

Research

The clinical implications of adult-onset henoch-schonelin purpura.

Clinical and molecular allergy : CMA, 2011

Research

Henoch-Schönlein purpura nephritis.

Pediatric nephrology (Berlin, Germany), 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.